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Abstract
Introduction: We identified three patients who developed anorectal stenosis after successful treatment with anti-
tumor necrosis factor a (anti-TNF-a) agents.
Case presentation: Two patients, a 24-year-old Irish Caucasian man and a 64-year-old Irish Caucasian woman,
developed symptoms attributable to anorectal stenosis four to six weeks after treatment. A further patient, a
25-year-old Irish Caucasian male, presented three years after treatment with anorectal stenosis, having been
asymptomatic with his stenosis for the preceding three years. No patients had evidence of active inflammation at
time of representation or had previous anal canal surgery.
Conclusion: Anorectal stenosis in these patients appears to be independent of active inflammation. No other
cause of new stenosis could be identified. We postulate that rapid clinical response to anti-TNF-a agents led to
aberrant mucosal healing. This in turn led to anorectal stenosis. This is the first report of this complication in
association with the use of biologic agents.
Introduction
Tumor necrosis factor a antibodies (anti-TNF-a)h a v e
become widely used in the treatment of chronic inflam-
matory bowel disease (IBD). TNF-a is a proinflamma-
tory cytokine that plays a central role in the
pathogenesis of IBD. Currently, infliximab is licensed for
use in moderate to severe Crohn’s disease (CD) and
ulcerative colitis (UC) [1,2]. Newer anti-TNF-a agents,
including adalimumab and more recently certolizumab
pegol, have been licensed for use in patients with CD.
Efficacy rates in excess of 40% to 60% have been
reported for infliximab [3-6]. These potent drugs are
tolerated well but are associated with potentially signifi-
cant adverse effects. The most commonly reported
adverse event associated with their use is an increased
risk of infections [7,8]. Infusion reactions or anaphylaxis
occur in a small proportion of patients (~5%) [6]. Most
concerns about the use of these biologic agents relates
to reports of hematologic and lymphoproliferative malig-
nancies [9]. Concerns regarding the exacerbation of CD-
associated small bowel strictures were raised when
infliximab was first used.
We report a case-series of three patients who pre-
sented with anorectal stenosis after successful treatment
with anti-TNF-a agents.
Case presentation
Case 1
Patient 1 is a 24-year-old Irish Caucasian man diagnosed
with CD at the age of 18 years. Endoscopy at the time
of diagnosis revealed active rectal and distal colonic
inflammation and the presence of a draining perineal
sinus. He was treated initially with a combination of
steroids and subsequently maintained in remission with
azathioprine. He has no other medical or surgical
problems.
His disease became active two years later despite
maintenance treatment with azathioprine. Repeat endo-
scopy confirmed active rectal and descending colonic
inflammation; there was no evidence of active perineal
disease. He was treated initially with an induction dose
of infliximab (5 mg/kg at 0, 2 and 6 weeks) in the sum-
mer of 2005. He had a partial response and was contin-
ued again on azathioprine.
His disease flared again in 2007. At this time his
laboratory, investigations suggested active disease (C-
reactive protein [CRP] 53 mg/L, 0-4 mg/L is normal).
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revealed active left-sided colonic and rectal inflamma-
tion. He had no evidence of active perineal disease at
this time. His Harvey-Bradshaw Index (HBI; score ≥7
indicates likely remission) was 9. Because of his partial
response with infliximab, he was treated with adalimu-
mab. He received 160 mg at induction and thereafter
was maintained on 80 mg subcutaneously every other
week. He made a rapid recovery, with resolution of his
symptoms of diarrhea, pain and bleeding per rectum.
His laboratory test results also improved (CRP <4) after
treatment with adalimumab.
However, he presented one month after his com-
mencement on adalimumab with ‘diarrhea’again. His
laboratory investigations revealed normal inflammatory
markers (CRP <4), and his HBI had improved to 3. On
further questioning, he admitted to feeling as well as he
ever had. However, he was concerned about the recur-
rence of his ‘diarrhea’ and had started to become una-
ware of the passage of liquid stool. This was believed to
be consistent with a diagnosis of ‘overflowdiarrhea.’ A
rectal examination was attempted but was not possible
because of anal stenosis.
He was admitted for endoscopic evaluation and was
found to have a previously undocumented anal stenosis,
with hard stool easily palpable above his stenosed anor-
ectal canal. Endoscopy revealed a scarred but nonin-
flamed colon. His anorectal stenosis was treated with a
manual dilatation under anaesthesia, and he was subse-
quently discharged home. He required a further dilata-
tion six weeks later. He has remained in clinical
remission for three years maintained on adalimumab.
Case 2
Patient 2 is a 64-year-old Irish Caucasian woman diag-
nosed with CD involving her entire colon (including
active disease noted in her rectum) and orofacial granu-
lomatosis. She had no evidence of perineal disease. She
initially presented with diarrhea related to CD and was
treated with corticosteroids. She was subsequently trea-
ted with azathioprine but was unable to tolerate it.
Her symptoms persisted and inflammatory markers
deteriorated (erythrocyte sedimentation rate, 38 [refer-
ence range, 0-25 mm/h]; albumin, 27 [reference range,
35-50 g/L); hemoglobin, 9.4 (reference range, 13-17 g/
dL); CRP, 9). Her HBI at this time was 7. She was sub-
sequently started on infliximab (receiving 5 mg/kg at 0,
2 and 6 weeks). She again made a rapid recovery. Her
symptoms and laboratory investigations all improved.
However, she presented one month after starting on
infliximab with a new problem of constipation. Again,
on clinical examination, she was found to have a ste-
nosed anal canal. Her laboratory parameters had all nor-
malized, as had her HBI to 1. She was admitted for
endoscopic evaluation and was found to have a stenosed
anorectal canal with a noninflamed colon (Figure 1).
Her stricture was treated using balloon dilatation, and
she was discharged home with resolution of her symp-
toms. She was maintained on infliximab (at a dosage of
5 mg/kg every 8 weeks). Unfortunately, she has required
a further five dilatations of her anorectal canal, with
temporary interval improvement. She continued to have
problems and eventually required a diversion colostomy.
Case 3
Patient 3 is a 25-year-old Irish Caucasian man diagnosed
with CD colitis affecting the descending colon and rec-
tum. He presented with active disease three years pre-
viously. Endoscopic evaluation revealed active rectal and
colonic inflammation; his perineum appeared normal.
His laboratory investigations confirmed active inflamma-
tion with a CRP of 38. His HBI was 10 at the time of
presentation. He was treated initially with infliximab
(5 mg/kg at 0, 2 and 6 weeks) after failed corticosteroid
treatment. His disease responded rapidly. After he was
in remission (after three doses of infliximab), he was
switched to azathioprine and maintained on it. At a fol-
low-up colonoscopy eight weeks after starting inflixi-
mab, we noted a stenosed anorectal canal with a
quiescent colitis proximal to this. In the intervening
three years, the patient has remained well. He recently
represented with severe abdominal pain and constipa-
tion. His laboratory investigations were all normal (CRP
<4), and his HBI was calculated to be 2. He was found
Figure 1 Balloon dilatation of anorectal stenosis.T h i s
endoscopic picture shows the stenosis seen in patient 2. A balloon
has been advanced through the stricture and has been inflated in
the anorectal canal to dilate the patient’s stenosis.
Slattery et al. Journal of Medical Case Reports 2010, 4:226
http://www.jmedicalcasereports.com/content/4/1/226
Page 2 of 4to have an anorectal stenosis with hard stool proximal
to this. He was treated with mechanical bowel prepara-
tion, and a follow up colonoscopy revealed a normal
colon above a stenosed anorectal canal. He was subse-
quently treated with a balloon dilatation of his stricture.
His CD remains in remission.
Discussion
Benign anal stenosis is a rare complication of previous
anal surgery and is occasionally seen in patients with
active CD. Benign anal stenosis in the absence of
previous surgery after successful treatment with anti-
TNF-a agents has not previously been reported.
Theoretical concerns have been raised regarding the
occurrence of small bowel stricturing as a consequence
of rapid mucosal healing. There have been reports of
increased episodes of stricturing in some studies [10,11].
However, multivariate analysis has demonstrated that
infliximab use is not associated with increased small
bowel stricture development when corrected for con-
founders such as disease duration, disease severity and
so on [11]. More recent studies have actually demon-
strated a potential benefit to patients with small bowel
strictures [12,13].
The precise role of TNF-a in healing is not well estab-
lished. It has been shown that persistently elevated
TNF-a levels in patients with chronic skin ulcers may
impair healing and that treatment with infliximab may
reverse this process rapidly [14]. We postulate that rapid
clinical response to these potent biologic agents led to
rapid but aberrant mucosal healing at and around the
dentate line between anus and rectum (as opposed to
isolated bowel strictures). This in turn led to develop-
ment of anorectal stenosis int h e s ep a t i e n t s .N o n eo f
these patients had prior anal canal surgery or had evi-
dence of active perineal CD (eg, abscess, fistula) at the
time of representation (either endoscopically or bio-
chemically). All had colonic and rectal inflammation
before starting anti-TNF-a agents. No other precipitant
cause for anal canal stenosis could be determined in
these cases.
Two of our patients presented with symptoms four to
six weeks after administration of these biologic agents.
The third patient presented much later, but he was
found to have a degree of anal stenosis at follow-up
endoscopy shortly after administration of infliximab. At
this stage, he was asymptomatic and thus required no
intervention. However, this likely made him prone to
future problems with anorectal stenosis and explains his
later presentation.
Conclusion
This is the first report of anorectal stenosis in associa-
tion with CD after successful treatment with biologic
agents and in the absence of persisting active inflamma-
tion. Further research on the role of TNF-a and its
blocking agents in wound healing is warranted.
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